It is one of several new variants discovered in recent months, including others first found in England and Brazil
\nnews agency
\nJOHANNESBURG
\nThe new Covid-19 variant identified in South Africa can evade the antibodies that attack it in treatments using blood plasma from previously recovered patients, and may reduce the efficacy of the current line of vaccines, scientists said on Wednesday.
\nResearchers are racing to establish whether the vaccines currently being rolled out across the globe are effective against the so-called 501Y.V2 variant, identified by South African genomics experts late last year in Nelson Mandela Bay.
\n\u201cThis lineage exhibits complete escape from three classes of therapeutically relevant monoclonal antibodies,\u201d the team of scientists from three South African universities working with the National Institute for Communicable Diseases (NICD) wrote in a paper published in the bioRxiv journal.
\n\u201cFurthermore, 501Y.V2 shows substantial or complete escape from neutralising antibodies in COVID-19 convalescent plasma,\u201d they wrote, adding that their conclusions \u201chighlight the prospect of reinfection … and may foreshadow reduced efficacy of current spike-based vaccines.\u201d
\nThe 501Y.V2 variant is 50% more infectious than previous ones, South African researchers said this week. It has already spread to at least 20 countries since being reported to the World Health Organisation in late December.
\nIt is one of several new variants discovered in recent months, including others first found in England and Brazil.
\nThe variant is the main driver of South Africa\u2019s second wave of COVID-19 infections, which hit a new daily peak above 21,000 cases earlier this month, far above the first wave, before falling to about 12,000 a day.
\nConvalescent blood plasma from previous patients has not been shown to be effective when administered to severely ill patients requiring intensive care for COVID-19, but it is approved in several countries as an emergency measure.
\nBritish scientists and politicians have expressed concern that vaccines currently being deployed or in development could be less effective against the variant.
\nThe paper said it remained to be seen how effective current vaccines were against 501Y.V2, which would only be determined by large-scale clinical trials. But results showed the need for new vaccines to be designed to tackle the evolving threat, it said.<\/p>\n","protected":false},"excerpt":{"rendered":"
It is one of several new variants discovered in recent months, including others first found in England and Brazil news agency JOHANNESBURG The new Covid-19 variant identified in South Africa can evade the antibodies that attack it in treatments using blood plasma from previously recovered patients, and may reduce the efficacy of the current line […]<\/p>\n","protected":false},"author":2,"featured_media":169971,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-169964","post","type-post","status-publish","format-standard","has-post-thumbnail","category-world"],"yoast_head":"\n